Consultative sales leader with 20+ years of experience driving growth and digital transformation in global markets through strategic engagement and solution-based sales in SaaS, DaaS, and life sciences.
🔬 Building the Right Partnerships for mRNA Success One of the biggest challenges in mRNA development isn’t just the science—it’s finding the right partners to scale innovation into the clinic. This was the focus of today’s panel discussion led by Andreas Kuhn (BioNTech SE) at the #MRNASummit, featuring insights from Divita Gilles (DIVINCELL), Verena Mummert (Ethris), James Lee, PhD (Everest Medicines), and Vincent Serra (NEOVACS). 💡 Key Takeaways: ✅ Pharma engagement has shifted—companies now prioritize late-stage clinical programs over platform technologies, as Verena Mummert pointed out. Clinical data is king. ✅ CDMO bottlenecks are a real challenge—James Lee highlighted that US manufacturing capacity is limited, forcing companies to look for global partnerships. Gilles Divita emphasized the importance of planning early to avoid scalability issues. ✅ Investment is tougher than ever—Vincent Serra noted that in Europe, securing capital requires at least Phase 1 data, preferably Phase 2. James Lee shared insights on how NewCo models in China are gaining traction as a spinout strategy to attract investors. ✅ IP strategy is crucial—James Lee explained how some biotech firms prefer trade secrets over patents to maintain a competitive edge and protect proprietary technology. 🚀 The takeaway? Biotech-pharma partnerships are evolving. Clinical validation is now the key to securing funding and partnerships. CDMO capacity constraints demand early planning and multiple manufacturing strategies. And in this fast-moving space, companies must be flexible—licensing, co-development, and asset acquisition are all on the table. Exciting times ahead for mRNA therapeutics! What are your thoughts on these industry shifts? #mRNA #Biotech #Pharma #Partnerships #Innovation #DrugDevelopment